心玮医疗-B今日盘中股价大幅上涨5.35%，引起了市场的广泛关注。
消息面上，公司此前发布的2025年年度业绩显示其成功实现重大扭亏为盈。报告期内，公司实现营业收入4.08亿元，同比增长46.9%；净利润达到8334万元，相较2024年的亏损1362万元，业绩表现显著改善。同时，公司经营性现金流充沛，财务结构健康，毛利率提升，销售与管理费用率下降，运营效率持续优化。此外，治疗性产品收入占比首次突破50%，业务结构向更高价值领域转型。
公司的增长动力来自缺血性、出血性卒中及介入通路三大业务板块的梯次发力，其中出血性卒中业务收入同比暴增223.2%。海外市场拓展迅速，收入同比增长101.3%。未来，公司在介入式脑机接口等创新管线上布局领先，并计划提交A股科创板上市申请，这些积极因素共同提振了投资者信心，推动股价上扬。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.